Actively Recruiting
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Led by University of Sao Paulo General Hospital · Updated on 2026-03-11
200
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This interventional phase IV clinical trial will evaluate the efficacy, immunogenicity and safety of the adjuvanted recombinant herpes zoster vaccine (RZV) in adults with autoimmune rheumatic diseases (ARDs) receiving immunomodulatory monotherapy. Humoral immune response will be quantified by anti-glycoprotein E (anti-gE) antibody titers. Patients will receive two doses of RZV. Outcomes include seroconversion and geometric mean titers six weeks after completion of the vaccination schedule, persistence of antibody titers at one year, and incidence of confirmed herpes zoster during follow-up.
CONDITIONS
Official Title
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older.
- Diagnosis of an autoimmune rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis, Sj�f6gren syndrome, idiopathic inflammatory myopathies, or primary systemic vasculitis) according to validated classification criteria.
- Clinical stability at the time of enrollment, defined as no change in disease-modifying therapy or corticosteroid dose in the preceding four weeks and no evidence of infection or disease flare.
- Current use of hydroxychloroquine or sulfasalazine in monotherapy for at least three months prior to inclusion.
- Can be under prednisone use of 5mg/week.
- Ability and willingness to comply with study procedures and follow-up visits.
- Provision of written informed consent.
You will not qualify if you...
- Previous vaccination with recombinant zoster vaccine (RZV).
- History of herpes zoster or varicella infection within 12 months before enrollment.
- Concomitant use of systemic immunosuppressive therapy including but not limited to methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, biologics, or JAK inhibitors.
- Use of glucocorticoids >5mg/week.
- Acute febrile illness or active infection at the time of vaccination.
- Pregnancy or breastfeeding.
- Known hypersensitivity to any component of the recombinant zoster vaccine.
- History of Guillain-Barr�e9 syndrome.
- Any condition that, in the investigators' judgment, could interfere with study participation or interpretation of results.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital das Clínicas
São Paulo, São Paulo, Brazil, 05403-010
Actively Recruiting
Research Team
E
Eloisa Bonfa, Full Professor
CONTACT
C
Clovis Silva, Full Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here